Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

August 5, 2021 13:12:59
  • The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders
  • The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs
  • PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters at this year’s Canaccord Genuity Virtual Growth Conference, to be held virtually on August 10-12. Tryp is focused on developing psilocybin-based clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways ( Tryp Chairman and CEO Greg McKee stated that the company would be presenting an overview of the business and its pipeline – including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders. Tryp’s presentation will be held on August 10 at 3 p.m. EST. Register to view the presentation at Prior to this announcement, Tryp released a broadcast titled, “Psychedelics – Not Just for Mental Health Anymore,” highlighting the historical knowledge of psychedelics, such as peyote and psilocybin, and their healing effects, ( Modern-day research was hindered by the Controlled Substances Act of 1970, classifying psychedelics as Schedule I drugs with no medical use. In the last few years, research has been lifting this stigma, including research done by Johns Hopkins Medical showing that two doses of psilocybin in combination with psychotherapy generated reduced symptoms for adults suffering from major depression. (can we link to the trial here). Many psychedelic companies have focused on depression, but Tryp is confident that psilocybin can effectively treat other underserviced indications, including chronic pain and certain eating disorders. Tryp’s PFN program is focused on the development of psilocybin-based drug therapy for certain neuropsychiatric disorders. The psilocybin-based therapies have distinct advantages over other drugs currently on the market or in development, including:
  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction
PFN features Tryp’s lead drug candidate, TRP-8802, with an initial indication of fibromyalgia. Tryp plans to seek FDA approval to proceed to Phase 2a clinical trials to evaluate the drug as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients found in TRP-8802. So far in 2021, Tryp has achieved significant milestones, which include expanding its roster of world-class scientific advisors, initiating collaborations with world-renowned research institutions to advance clinical trials, advancing the manufacturing capability for synthetic psilocybin, and more. Tryp plans to continue achieving several other milestones before the end of 2021. These milestones include initiating at least two Phase 2a trials, announcing several new clinical research collaborations with leading academic research institutions, successful manufacturing and formulation of GMP synthetic psilocybin using proprietary methods, and filing for additional intellectual property applications. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California 415.949.5050 Office PsychedelicNewsWire is part of the InvestorBrandNetwork.